FrancophonIA/ELRC3.0 huggingface dataset:
English: MARKETING AUTHORISATION NUMBER EU/1/96/007/036
Estonian: MÜÜGILOA NUMBER EU/1/96/007/036
English: 50% of the insulin lispro in Humalog Mix50 KwikPen is dissolved in water and it works more quickly than normal human insulin because the insulin molecule has been changed slightly.
Estonian: 50 % Humalog Mix50 KwikPen`is sisalduvast lispro-insuliinist on vees lahustatud ja see toimib kiiremini kui normaalne iniminsuliin, kuna insuliini molekuli on veidi muudetud.
English: Important information about some of the ingredients of Humalog This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodiumfree'.
Estonian: Oluline teave Humalog'i mõningate koostisosade suhtes Ravim sisaldab vähem kui 1 mmol (23 mg) naatriumi annuses, see tähendab põhimõtteliselt “naatriumivaba”.
English: PACKAGE LEAFLET: INFORMATION FOR THE USER Humalog Mix25 100 units/ml KwikPen, suspension for injection in a pre-filled pen insulin lispro Each KwikPen delivers 1 - 60 units in steps of 1 units.
Estonian: Humalog Mix25 100 ühikut/ml KwikPen, süstesuspensioon pen-süstlis lispro-insuliin Iga KwikPen väljastab ühiku kaupa 1...60 ühikut.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Humalog Mix50 100 units/ml KwikPen, suspension for injection 50% insulin lispro and 50% insulin lispro protamine suspension Subcutaneous use
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE Humalog Mix50 100 ühikut/ml KwikPen süstesuspensioon 50 % lispro-insuliini ja 50 % lispro-insuliini protamiinsuspensiooni Nahaaluseks kasutamiseks
English: Humalog Mix25 100 units/ml, suspension for injection in vial insulin lispro
Estonian: Humalog Mix25 100 ühikut/ml süstesuspensioon viaalis lispro-insuliin
English: NAME OF THE MEDICINAL PRODUCT Humalog 100 units/ml KwikPen, solution for injection in a pre-filled pen Insulin lispro
Estonian: RAVIMPREPARAADI NIMETUS Humalog 100 ühikut/ml KwikPen süstelahus pen-süstlis Lispro-insuliin
English: Conditions which may make the early warning symptoms of hypoglycaemia different or less pronounced include long duration of diabetes, intensified insulin therapy, diabetic nerve disease or medications such as beta-blockers.
Estonian: Seisunditeks, mis võivad muuta või vähendada hüpoglükeemia varajasi hoiatavaid sümptomeid, on pikaajaline suhkurtõbi , intensiivne insuliinravi, diabeetiline neuropaatia või mõned ravimid, nt. beetablokaatorid.
English: When administered subcutaneously care should be taken when injecting Humalog Mix50 to ensure that a blood vessel has not been entered.
Estonian: Humalog Mix50 süstimisel naha alla tuleb veenduda, et nõel ei ole sattunud veresoonde.
English: • Cartridges containing Humalog Mix25 should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
Estonian: • Vahetult enne süstimist tuleb insuliini uueks suspendeerimiseks Humalog Mix25 sisaldavat kolbampulli peopesade vahel kümme korda veeretada ja kümme korda 1800 võrra pöörata, kuni selles paiknev insuliin näib ühtlaselt hägune või piimjas.
English: 50% of the insulin lispro in Humalog Mix50 is dissolved in water and it works more quickly than normal human insulin because the insulin molecule has been changed slightly.
Estonian: 50 % Humalog Mix50-s sisalduvast lispro-insuliinist on vees lahustatud ja see toimib kiiremini kui normaalne iniminsuliin, kuna insuliini molekuli on veidi muudetud.
English: Do NOT use Humalog Mix50 - if you think hypoglycaemia (low blood sugar) is starting.
Estonian: ÄRGE kasutage Humalog Mix50 - Kui teile tundub, et algamas on hüpoglükeemia (madal veresuhkur).
English: 25% of the insulin lispro in Humalog Mix25 is dissolved in water and it works more quickly than normal human insulin because the insulin molecule has been changed slightly.
Estonian: 25 % Humalog Mix25-s sisalduvast lispro-insuliinist on vees lahustatud ja see toimib kiiremini kui normaalne iniminsuliin, kuna insuliini molekuli on veidi muudetud.
English: The suspension is contained in type I flint glass cartridges, sealed with halobutyl disc seals and plunger heads and secured with aluminium seals.
Estonian: Suspensioon on I tüüpi flintklaasist kolbampullis, mis on kinni pitseeritud halobutüülist diski ja kolvi kaanega ning mida kaitseb alumiiniumplomm.
English: Instructions for Use Humalog 100 units/ml Junior KwikPen, solution for injection in a pre-filled pen insulin lispro
Estonian: Humalog 100 ühikut/ml Junior KwikPen süstelahus pen-süstlis Lispro-insuliin
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Humalog Mix25 100 units/ml KwikPen, suspension for injection 25% insulin lispro and 75% insulin lispro protamine suspension Subcutaneous use
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE Humalog Mix25 100 ühikut/ml KwikPen süstesuspensioon 25 % lispro-insuliini ja 75 % lispro-insuliini protamiinsuspensiooni Subkutaanne
English: Unused Pens
Estonian: Kasutusel mitteolevad pen-süstlid
English: Important information about some of the ingredients of Humalog Mix25 KwikPen This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodiumfree'.
Estonian: Oluline teave Humalog Mix25 KwikPen'i mõningate koostisosade suhtes Ravim sisaldab vähem kui 1 mmol (23 mg) naatriumi annuses, see tähendab põhimõtteliselt “naatriumivaba”.
English: Needle
Estonian: tumehall
English: Your doctor may tell you to use Humalog Mix50 as well as a longer-acting insulin.
Estonian: Arst võib teil käskida kasutada Humalog Mix50 koos pika toimeajaga insuliiniga.
English: The rapid onset and early peak of activity of Humalog itself is observed following the subcutaneous administration of Humalog Mix50.
Estonian: Humalog Mix50 subkutaanse manustamise järel võib täheldada Humalogi enda toime kiiret saabumist ja kulmineerumist.
English: What Humalog Mix50 100 units/ml suspension for injection in cartridge looks like and contents of the pack
Estonian: Mida Humalog Mix50 100 ühikut/ml süstesuspensioon kolbampullis sisaldab:
English: MARKETING AUTHORISATION NUMBERS EU/1/96/007/004
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/96/007/004
English: MARKETING AUTHORISATION NUMBERS EU/1/96/007/006
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/96/007/006
English: 5 pre-filled pens of 3 ml
Estonian: 5 pen-süstlit, 3 ml
English: • Cartridges containing Humalog Mix50 should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
Estonian: • Vahetult enne süstimist tuleb insuliini uueks suspendeerimiseks Humalog Mix50 sisaldavat kolbampulli peopesade vahel kümme korda veeretada ja kümme korda 1800 võrra pöörata, kuni selles paiknev insuliin näib ühtlaselt hägune või piimjas.
English: NAME OF THE MEDICINAL PRODUCT Humalog Mix25 100 units/ml KwikPen, suspension for injection in a pre-filled pen 25% insulin lispro and 75% insulin lispro protamine suspension
Estonian: RAVIMPREPARAADI NIMETUS Humalog Mix25 100 ühikut/ml KwikPen süstesuspensioon pen-süstlis 25 % lispro-insuliini ja 75 % lispro-insuliini protamiinsuspensiooni
English: Pen Body Dose Window
Estonian: Pen'i korpus Annuse aken
English: Insulin lispro
Estonian: Katteko rgi kinniti
English: What Humalog Mix25 100 units/ml KwikPen, suspension for injection looks like and contents of the pack
Estonian: Mida Humalog Mix25 100 ühikut/ml KwikPen süstesuspensioon sisaldab:
English: Humalog Mix50 100 units/ml KwikPen, suspension for injection is a white, sterile suspension and contains 100 units of insulin lispro in each millilitre (100 units/ml) suspension for injection.
Estonian: Kuidas Humalog Mix50 100 ühikut/ml KwikPen süstesuspensioon välja näeb ja pakendi sisu Humalog Mix50 100 ühikut/ml KwikPen süstesuspensioon on valge, steriilne suspensioon ja sisaldab 100 toimeühikut lispro-insuliini igas milliliitris (100 ühikut/ml) süstesuspensioonina.
English: How to store Humalog Junior KwikPen
Estonian: Kuidas Humalog Junior KwikPen`i säilitada
English: NAME OF THE MEDICINAL PRODUCT Humalog Mix50 100 units/ml suspension for injection in cartridge 50% insulin lispro and 50% insulin lispro protamine suspension
Estonian: RAVIMPREPARAADI NIMETUS Humalog Mix50 100 ühikut/ml süstesuspensioon kolbampullis 50 % lispro-insuliini ja 50 % lispro-insuliini protamiinsuspensiooni
English: Do not transfer insulin from your Humalog 200 units/ml KwikPen to a syringe.
Estonian: Ärge kandke insuliini Humalog 200 ühikut/ml KwikPen'ist üle tavasüstlasse.
English: PACKAGE LEAFLET: INFORMATION FOR THE USER Humalog Mix50 100 units/ml KwikPen, suspension for injection in a pre-filled pen insulin lispro Each KwikPen delivers 1 - 60 units in steps of 1 units.
Estonian: Humalog Mix50 100 ühikut/ml KwikPen, süstesuspensioon pen-süstlis lispro-insuliin Iga KwikPen väljastab ühiku kaupa 1...60 ühikut.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Humalog 100 units/ml KwikPen, solution for injection Insulin lispro
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE Humalog 100 ühikut/ml KwikPen süstelahus Lispro-insuliin
English: Important information about some of the ingredients of Humalog Mix25 This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodiumfree'.
Estonian: Oluline teave Humalog Mix25 mõningate koostisosade suhtes Ravim sisaldab vähem kui 1 mmol (23 mg) naatriumi annuses, see tähendab põhimõtteliselt “naatriumivaba”.
English: MARKETING AUTHORISATION NUMBERS EU/1/96/007/002
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/96/007/002
English: Marketing Authorisation Holder and Manufacturer Humalog Mix25 100 units/ml suspension for injection in vial is made by:
Estonian: Humalog Mix25 100 ühikut/ml süstesuspensiooni viaalis toodab:
English: Important information about some of the ingredients of Humalog KwikPen This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodiumfree'.
Estonian: Oluline teave Humalog KwikPen'i mõningate koostisosade suhtes Ravim sisaldab vähem kui 1 mmol (23 mg) naatriumi annuses, see tähendab põhimõtteliselt “naatriumivaba”.
English: MARKETING AUTHORIZATION HOLDER Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
Estonian: Müügiloa hoidja Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Holland.
English: What Humalog Mix25 100 units/ml suspension for injection in cartridge looks like and contents of the pack
Estonian: Mida Humalog Mix25 100 ühikut/ml süstesuspensioon kolbampullis sisaldab:
English: NAME OF THE MEDICINAL PRODUCT Humalog 100 units/ml solution for injection in cartridge Insulin lispro
Estonian: RAVIMPREPARAADI NIMETUS Humalog 100 ühikut/ml süstelahus kolbampullis Lispro-insuliin
English: Humalog Mix25 100 units/ml suspension for injection is a white, sterile suspension and contains 100 units of insulin lispro in each millilitre (100 units/ml) suspension for injection.
Estonian: Kuidas Humalog Mix25 100 ühikut/ml süstesuspensioon viaalis välja näeb ja pakendi sisu Humalog Mix25 100 ühikut/ml süstesuspensioon on valge, steriilne suspensioon ja sisaldab 100 toimeühikut lispro-insuliini igas milliliitris (100 ühikut/ml) süstesuspensioonina.
English: Important information about some of the ingredients of Humalog Mix50 This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodiumfree'.
Estonian: Oluline teave Humalog Mix50 mõningate koostisosade suhtes Ravim sisaldab vähem kui 1 mmol (23 mg) naatriumi annuses, see tähendab põhimõtteliselt “naatriumivaba”.
English: NAME OF THE MEDICINAL PRODUCT Humalog Mix25 100 units/ml suspension for injection in vial 25% insulin lispro and 75% insulin lispro protamine suspension
Estonian: RAVIMPREPARAADI NIMETUS Humalog Mix25 100 ühikut/ml süstesuspensioon viaalis 25 % lispro-insuliini ja 75 % lispro-insuliini protamiinsuspensiooni
English: Injecting Humalog Mix50
Estonian: Humalog Mix50 süstimine
English: PRODUCT Humalog 200 units/ml KwikPen, solution for injection in a pre-filled pen
Estonian: RAVIMPREPARAADI NIMETUS Humalog 200 ühikut/ml KwikPen, süstelahus pen-süstlis
English: Marketing Authorisation Holder and Manufacturer Humalog 100 units/ml KwikPen, solution for injection is made by:
Estonian: Humalog KwikPen 100 ühikut/ml süstelahust toodab:
English: Put the cartridge into the pen.
Estonian: Asetage otsik pen-süstlile tagasi.
English: Pioglitazone should be discontinued, if any deterioration in cardiac symptoms occurs.
Estonian: Mistahes kardiaalsete sümptomite ägenemise korral tuleb ravi pioglitasooniga ära jätta.
English: NAME OF THE MEDICINAL PRODUCT Humalog Mix25 100 units/ml suspension for injection in cartridge 25% insulin lispro and 75% insulin lispro protamine suspension
Estonian: RAVIMPREPARAADI NIMETUS Humalog Mix25 100 ühikut/ml süstesuspensioon kolbampullis 25 % lispro-insuliini ja 75 % lispro-insuliini protamiinsuspensiooni
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Humalog 100 units/ml solution for injection in vial Insulin lispro
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE Humalog 100 ühikut/ml süstelahus viaalis Lispro-insuliin
English: Contains glycerol, zinc oxide, dibasic sodium phosphate7H20 with m-cresol as a preservative in water for injection.
Estonian: Sisaldab glütserooli, tsinkoksiidi dinaatriumvesinikfosfaatheptahüdraat, säilitusainena metakresooli süstevees.
English: Humalog Mix25 100 units/ KwikPen, suspension for injection is a white, sterile suspension and contains 100 units of insulin lispro in each millilitre (100 units/ml) suspension for injection.
Estonian: Kuidas Humalog Mix25 100 ühikut/ml KwikPen süstesuspensioon välja näeb ja pakendi sisu Humalog Mix25 100 ühikut/ml KwikPen süstesuspensioon on valge, steriilne suspensioon ja sisaldab 100 toimeühikut lispro-insuliini igas milliliitris (100 ühikut/ml) süstesuspensioonina.
English: • Check the number in the Dose Window.If you see “0” in the Dose Window, you have received the full amount you dialled.
Estonian: Kui Te näete annuseaknas “0”, olete Te saanud kogu oma valitud annuse.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING INTERMEDIATE CARTON (without blue box) component of a multipack - Vial
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED VAHEKARP (ilma blue box`ita) multipakendi osa-viaal
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Humalog Mix50 100 units/ml suspension for injection in cartridge 50% insulin lispro and 50% insulin lispro protamine suspension Subcutaneous use
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE Humalog Mix50 100 ühikut/ml süstesuspensioon kolbampullis 50 % lispro-insuliini ja 50 % lispro-insuliini protamiinsuspensiooni Subkutaanne
English: PACKAGE LEAFLET: INFORMATION FOR THE USER Humalog 100 units/ml KwikPen, solution for injection in a pre-filled pen insulin lispro Each KwikPen delivers 1 - 60 units in steps of 1 units.
Estonian: Humalog KwikPen 100 ühikut/ml, süstelahus pen-süstlis lispro-insuliin Iga KwikPen väljastab ühiku kaupa 1...60 ühikut.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Humalog Mix25 100 units/ml suspension for injection in vial 25% insulin lispro and 75% insulin lispro protamine suspension Subcutaneous use
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE Humalog Mix25 100 ühikut/ml süstesuspensioon viaalis 25 % lispro-insuliini ja 75 % lispro-insuliini protamiinsuspensiooni Subkutaanne
English: What Humalog Mix25 100 units/ml suspension for injection in vial looks like and contents of the pack
Estonian: Mida Humalog Mix25 100 ühikut/ml süstesuspensioon viaalis sisaldab:
English: Humalog Mix50 100 units/ml suspension for injection is a white, sterile suspension and contains 100 units of insulin lispro in each millilitre (100 units/ml) suspension for injection.
Estonian: Humalog 100 ühikut/ml süstelahus on steriilne, selge, värvitu vesilahus, mis sisaldab 100 ühikut lispro-insuliini igas milliliitris (100 ühikut/ml) süstelahusena.
English: 1 pre-filled pen of 3 ml
Estonian: 1 pen-süstel, 3 ml
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Humalog Mix25 100 units/ml suspension for injection in cartridge 25% insulin lispro and 75% insulin lispro protamine suspension Subcutaneous use
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE Humalog Mix25 100 ühikut/ml süstesuspensioon kolbampullis 25 % lispro-insuliini ja 75 % lispro-insuliini protamiinsuspensiooni Subkutaanne
English: The rapid onset and early peak of activity of insulin lispro is observed following the subcutaneous administration of Humalog Mix50.
Estonian: Pärast Humalog Mix50 subkutaanset manustamist on täheldatud kiiret lispro-insuliini toime algust ja varajast maksimaalse taseme saabumist.
English: • acetyl salicylic acid,
Estonian: salbutamool, terbutaliin).
English: It is available as tablets (20 mg, 40 mg and 80 mg).
Estonian: Seda turustatakse tablettidena (20 mg, 40 mg ja 80 mg).
English: It also allows the heart to pump blood more easily, which can help to reduce the risk of future cardiovascular problems
Estonian: Lisaks hõlbustab ravim südame tööd vere pumpamisel, mis vähendab tulevaste kardiovaskulaarsete probleemide riski.
English: The doctor should monitor the patient's blood pressure closely when starting Telmisartan Teva Pharma, and may decide to adjust the patient's blood pressure-lowering medication.
Estonian: Arst peab Telmisartan Teva Pharmaga ravi alustamisel patsiendi vererõhku hoolikalt jälgima ning ta võib kohandada patsiendi vererõhku alandava ravimi annust.
English: pressure is not reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.
Estonian: võib annust suurendada 80 mg-ni või täiendada ravi mõne teise kõrgvererõhuravimiga, näiteks hüdroklorotiasiidiga.
English: For the treatment of essential hypertension, the usual recommended dose of Telmisartan Teva Pharma is 40 mg once a day, but some patients may benefit from using a 20-mg dose.
Estonian: Essentsiaalse hüpertensiooni ravis on Telmisartan Teva Pharma tavaline soovitatav annus 40 mg üks kord ööpäevas, kuid mõnele patsiendile võib piisata ka 20 mg annusest.
English: The European Commission granted a marketing authorisation valid throughout the EU for Telmisartan Teva Pharma on 3 October 2011.
Estonian: Euroopa Komisjon andis Telmisartan Teva Pharma müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 3. oktoobril 2011.
English: Telmisartan Teva Pharma is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks or strokes.
Estonian: Telmisartan Teva Pharmat kasutatakse ka kardiovaskulaarsete probleemide (südame- ja veresoonkonnaprobleemide), näiteks südameinfarkti ja insuldi ennetamiseks.
English: The full EPAR for Telmisartan Teva Pharma can be found on the Agency's website: EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Telmisartan Teva Pharma kohta on ameti veebilehelEMA website/Find medicine/Human medicines/European Public Assessment Reports.
English: Telmisartan Teva Pharma telmisartan
Estonian: Telmisartan Teva Pharma telmisartaan
English: This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a heart attack or stroke.
Estonian: See vähendab vererõhku ja kõrgvererõhu riske, näiteks südameinfarkti või insuldi esinemist.
English: For more information about treatment with Telmisartan Teva Pharma, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Telmisartan Teva Pharmaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Because Telmisartan Teva Pharma is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Telmisartan Teva Pharma on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: The active substance in Telmisartan Teva Pharma, telmisartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Estonian: Telmisartan Teva Pharma toimeaine telmisartaan on angiotensiin II retseptori antagonist, mis blokeerib organismis hormooni angiotensiin II toime.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Telmisartan Teva Pharma.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Patients with mild or moderately reduced liver function should not receive doses higher than 40 mg a day
Estonian: Kerge või mõõduka neerupuudulikkusega patsiendid ei tohi võtta suuremat annust kui 40 mg üks kord ööpäevas.
English: Telmisartan Teva Pharma is used to treat essential hypertension (high blood pressure) in adults.
Estonian: Telmisartan Teva Pharmat kasutatakse essentsiaalse hüpertensiooni (kõrgvererõhutõve) ravimiseks täiskasvanutel.
English: The CHMP concluded that, in accordance with EU requirements, Telmisartan Teva Pharma has been shown to have comparable quality and to be bioequivalent to Micardis.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Telmisartan Teva Pharma võrreldav kvaliteet ja bioekvivalentsus ravimiga Micardis.
English: The Committee recommended that Telmisartan Teva Pharma be given marketing authorisation.
Estonian: Komitee soovitas anda Telmisartan Teva Pharma müügiloa.
English: This means that Telmisartan Teva Pharma is similar to a ‘reference medicine' already authorised in the European Union (EU) called Micardis.
Estonian: See tähendab, et Telmisartan Teva Pharma on sarnane võrdlusravimiga Micardis, millel juba on Euroopa Liidus müügiluba.
English: Telmisartan Teva Pharma is a medicine that contains the active substance telmisartan.
Estonian: Telmisartan Teva Pharma on ravim, mis sisaldab toimeainena telmisartaani.
English: This is a summary of the European Public Assessment Report (EPAR) for Telmisartan Teva Pharma.
Estonian: See on ravimi Telmisartan Teva Pharma Euroopa avaliku hindamisaruande kokkuvõte.
English: Telmisartan Teva Pharma is a ‘generic medicine'.
Estonian: Telmisartan Teva Pharma on geneeriline ravim.
English: If the target blood
Estonian: Kui see ei alanda vererõhku,
English: Because Telmisartan Teva Pharma is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Micardis.
Estonian: Et Telmisartan Teva Pharma on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Telmisartan Teva Pharma bioekvivalentsust võrdlusravimiga Micardis.
English: Therefore, the CHMP's view was that, as for Micardis, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Micardise korral, ületab ravimi Telmisartan Teva Pharma kasulikkus sellega kaasnevad riskid.
English: Why has Telmisartan Teva Pharma been approved?
Estonian: Miks Telmisartan Teva Pharma heaks kiideti?
English: Other information about Telmisartan Teva Pharma:
Estonian: Muu teave Telmisartan Teva Pharma kohta
English: How has Telmisartan Teva Pharma been studied?
Estonian: Kuidas Telmisartan Teva Pharmat uuriti?
English: What is Telmisartan Teva Pharma?
Estonian: Mis on Telmisartan Teva Pharma?
English: What are the benefit and risk of Telmisartan Teva Pharma?
Estonian: Milles seisneb Telmisartan Teva Pharma kasulikkus ja mis riskid ravimiga kaasnevad?
English: How does Telmisartan Teva Pharma work?
Estonian: Kuidas Telmisartan Teva Pharma toimib?
English: What is Telmisartan Teva Pharma used for?
Estonian: Milleks Telmisartan Teva Pharmat kasutatakse?
English: How is Telmisartan Teva Pharma used?
Estonian: Kuidas Telmisartan Teva Pharmat kasutatakse?